AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
AstraZeneca Posts Bumper Earnings On Strong Sales From Cancer Drugs, Sticks To Annual Guidance
Thursday, AstraZeneca Plc (NASDAQ:AZN) reported first-quarter sales of $12.68 billion, up 17% year over year (+19% at constant currency), slightly below the consensus of $11.83 billion.
週四，阿斯利康公司（納斯達克股票代碼：AZN）公佈的第一季度銷售額爲126.8億美元，同比增長17％（按固定匯率計算增長19％），略低於市場普遍預期的118.3億美元。
This was fueled by an 18% increase in Product Sales and continued growth in Alliance Revenue from partnered medicines.
這得益於產品銷售額增長18％以及聯盟合作藥品收入的持續增長。
The company's adjusted EPADS reached $1.03, missing the consensus of $1.22.
該公司調整後的EPADS達到1.03美元，未達到1.22美元的共識。
R&D expenses rose about 18% to $2.7 billion, while sales, general, and administration costs were up 13% on higher marketing spend for new drug launches.
研發費用增長了約18％，達到27億美元，而銷售、一般和管理成本增長了13％，原因是新藥上市的營銷支出增加。
AstraZeneca's top business, oncology, delivered a 26% jump in first-quarter sales to $5.12 billion.
阿斯利康最大的業務腫瘤學第一季度銷售額增長了26％，達到51.2億美元。
Top-selling cancer drugs were Tagrisso and Imfinzi, which generated $1.6 billion and $1.11 billion, up 12% and 29%, respectively.
最暢銷的抗癌藥物是塔格里索和伊芬齊，它們創造了16億美元和11.1億美元的收入，分別增長了12％和29％。
Cardiovascular, Renal, and Metabolism (CVRM) sales increased 20% (up 23 at CER)% to $3.1 billion.
心血管、腎臟和新陳代謝（CVRM）的銷售額增長了20％（按恒定匯率增長23％），達到31億美元。
Farxiga sales were up 43% (45% at CER) with continued demand growth and the launch of an authorized generic in the U.S., Lokelma was up 16% (19% at CER), roxadustat up 24% (28% at CER), Brilinta decreased 3% (1% at CER).
Farxiga的銷售額增長了43％（按恒定匯率計算爲45％），這要歸因於需求的持續增長以及在美國推出的授權仿製藥Lokelma增長了16％（按CER計算爲19％），roxadustat增長了24％（按恒定匯率計算爲28％），Brilinta下降了3％（按恒定匯率計算爲1％）。
R&I Respiratory & Immunology sales increased 15% (17% CER).
R＆I呼吸與免疫學的銷售額增長了15％（CER爲17％）。
Continued strong growth from Fasenra up 6% (6% CER), Breztri up 52% (54% CER).
Saphnelo sales were up 94% (95% CER), and Tezspire was up >2x (>2x CER). Symbicort was up 12% (14% CER).
Fasenra持續強勁增長，上漲6％（CER6％），Breztri上漲52％（CER54％）。
Saphnelo的銷售額增長了94％（95％的CER），Tezspire的銷售額增長了2倍以上（超過2倍的CER）。Symbicort上漲了12％（CER爲14％）。
Rare Disease drug sales increased by 12% (+16% at CER) to $2.1 billion.
罕見病藥物的銷售額增長了12％（按CER計算增長了16％），達到21億美元。
Ultomiris revenues were up 32% (34% at CER), partially offset by a decline in Soliris of 11% (8% at CER)
Strensiq is up 20% (21% at CER), and Koselugo is up 68% (82% at CER), reflecting strong patient demand and tender market order timing.
Ultomiris收入增長了32％（按恒定匯率計算爲34％），但部分被Soliris下降11％（按CER計算爲8％）所抵消
Strensiq上漲了20％（按CER計算爲21％），Koselugo上漲了68％（按CER計算爲82％），這反映了強勁的患者需求和投標市場訂單的時機。
Guidance: For fiscal year 2024, AstraZeneca reaffirms total revenues and core EPS are expected to increase by a low double-digit to low teens percentage at constant exchange rates.
指導方針：對於2024財年，阿斯利康重申，按固定匯率計算，總收入和核心每股收益預計將以兩位數的低位數增長至十幾歲以下。
Price Action: At the last check Thursday, AZN shares were up 4.99% at $74.75 during the premarket session.
價格走勢：在週四的最後一次檢查中，AZN股價在盤前交易時段上漲了4.99％，至74.75美元。
譯文內容由第三人軟體翻譯。